Johnson & Johnson expects to sell $3-3.5 billion in Covid vaccines in 2022

Pharmaceuticals group Johnson & Johnson expects to sell between $3 billion and $3.5 billion of its single-dose Covid-19 vaccine in 2022, slightly more than in 2021, according to a release presenting its results. Tuesday.

The group, which has been selling the product at cost since the start of the pandemic, sold it for 2.385 billion dollars last year.

Read alsoMedical innovation, pillar of the “new” Johnson & Johnson

Johnson & Johnson was still planning to sell 2.5 billion dollars for the year as a whole in October, but the production of the serum was notably disrupted by problems at a factory in Baltimore.

This is far from the sales of other American laboratories that have developed vaccines against Covid.

Net profit up 172%

Pfizer thus planned at the beginning of November to sell a total of 36 billion dollars of the product developed in partnership with the German biotech BioNTech in 2021, and is counting on the additional sale of 29 billion dollars in 2022. Moderna for its part should have sold for 17, 5 billion dollars of its anti-Covid vaccine in 2021 and received at the beginning of the year for 18.5 billion dollars of orders for 2022, with options for 3.5 billion additional dollars, had indicated its boss, Stéphane Bancel, during a conference on January 10.

Total revenue for Johnson & Johnson, which in addition to drugs sells products like Neutrogena creams and medical equipment, disappointed a little in the fourth quarter, reaching $24.8 billion, where analysts had expected 25 ,3 billions.

Its net profit for its part climbed 172% to 4.74 billion dollars.

Reported by share and excluding exceptional items, it reached 2.13 dollars, slightly above forecasts.

Read alsoCovid-19: vaccines retain very high efficacy against severe cases of Omicron, according to US data

Over the full year, the group's turnover amounted to 93.8 billion dollars and its net profit increased by 42% to 20.89 billion dollars.

The action fell 1.4% in electronic trading before the opening of the New York Stock Exchange.